



AIRA
AMERICAN IMMUNIZATION
REGISTRY ASSOCIATION

Discovery Session: Centralized Reminders, Measurable Results!

February 23, 2026
4:00 p.m. ET



Today's Presenters

- **Francis Pacillo**, formerly of Alaska's Department of Health and Social Services
- **Marisa Langdon-Embry, MSc**, Data Governance and Quality Assurance Analyst, Bureau of Immunizations, New York City





docket[®]

AIRA Discovery Session
February 23, 2026

Effect of Push Notification Reminders on Early Flu Vaccination in Alaska


Francis Pacillo¹ Nathan Scott² Monette Schwoerer¹

¹ Alaska Department of Health

² Docket Health, Inc.

I Background


Cumulative Percent Vaccinated for Flu in Alaska (2023–24 Season)



Problem: CDC recommends that people get a flu vaccine by the end of October. In 2023, only **14.6%** of Alaska residents had received a flu vaccine by that point.

I Background

Cumulative Percent Vaccinated for Flu by Age Group (2023–24 Season)



Vaccination Gap: By the end of October 2023, only **9.1%** of children (0-17), **12.3%** of adults (18-64), and **33.8%** of older adults (65+) in Alaska had received a flu vaccine.



2024 FALL & WINTER RECOMMENDED IMMUNIZATIONS:



Alaska Department of Health
Immunization Program
3601 C St, Suite 540
Anchorage, AK 99503

For everyone 6 months & older:

- ✓ Flu shot
- ✓ COVID shot

If you're pregnant or have a child under 8 months old:

- ✓ Talk to your doctor about RSV immunizations to protect your baby

If you're 60 years or older:

- ✓ Talk to your doctor about protection against RSV

Questions? Contact your health care provider or learn more at [Vaccinate.Alaska.Gov](https://www.vaccinate.alaska.gov)



Did you know? You can check your Alaska immunization records anytime with the free *docket* app on a phone or computer.




Context: Alaska's Immunization Program sends **costly** reminder/recall postcards statewide to promote vaccination.

I Background



Potential Solution: Push notification reminders may offer a **zero-cost** way to boost early flu vaccination.

I Background



Note: From *Guardians of Immunization Adherence: Cosmic Reminder/Recall*, presented at [AIRA 2024 National Meeting](#).

Workflow: Docket checks vaccine eligibility, sends reminders, and re-queries the IIS to update records and send recalls when needed.

Study Rationale

- Research suggests that mail and phone reminders increase vaccination uptake, but the impact of mobile push notifications remains unknown.
- Given their **scalability** and **zero-cost**, push notifications may be a promising tool to promote vaccination.

Research Questions

1. **Effectiveness:** Does the intervention improve vaccination uptake?
2. **Timing:** Does the intervention initiate earlier vaccination?
3. **Subgroups:** Is the intervention more effective in younger adults?

Pilot Study Methodology

Study Design

- **Study design:** Randomized controlled trial (Sep-Oct 2024)
- **Intervention:** Mobile app push notifications
- **Outcome:** Influenza vaccination
- **Cadence:** 1 reminder + 1 recall after 30 days


Population

- **Population:** Alaskan adults with Docket accounts and push notifications enabled.
- **Eligibility Criteria:** Adults (18+) with Docket accounts, enabled notifications, and complete IIS records.

Data Analysis

- **Measures of Association:** Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional-hazards models. Analyses conducted in R (v4.4.1).

II Methodology



* Subset of 17,730 total Docket users.


Participant Selection: Issues in study execution impacted the final analysis, as many were excluded post-randomization.

II Methodology

First Notification Sent
(September 1, 2024)

Second Notification Sent
(October 1, 2024)

End of Experiment
(October 28, 2024)




Experiment Timeline: This pilot study tracked documented influenza vaccinations in Alaska's IIS from September 1 through October 28, 2024.

II Methodology

1


Transforming data elements



Created a time-to-event variable (days from study start to vaccination)

2

Estimating intervention effect on vaccination



Fit Cox proportional hazards models to estimate hazard ratios

3

Testing proportional hazard assumption



Evaluated model assumptions using Schoenfeld residuals

Statistical Analysis: We used R to conduct statistical analyses, applying Cox proportional-hazard models to estimate the intervention effect.

Table 1. Baseline statistics according to study arm

Characteristic	Category	Control (%)	Intervention (%)
Sex	Male	35.4	34.5
	Female	64.1	64.9
	Unknown	0.5	0.6
Race	White	53.1	56.6
	Black	3.2	1.9
	Asian	6.0	4.7
	Alaska Native/American Indian	13.0	12.2
	Native Hawaiian/Pacific Islander	1.4	0.6
	Other Race	23.3	23.9
Age	18-34	25.9	24.8
	35-64	43.9	40.4
	65+	30.2	34.8

Note: Based on the analyzed sample (n = 652 control, n = 678 intervention).

III Results

Figure 1. Median time to vaccination was 48 days in the intervention arm and 55 days in the control group




Table 2. Cox proportional-hazards model with age-interaction: push notification effect decreased with age

Model Term	HR	95% CI	P-value
Push Notification group (at age 0)	1.84	1.12 - 3.03	0.02
Age (continuous)	1.03	1.02 - 1.04	<0.001
Push Notification x Age (interaction)	0.99	0.98 - 1.00	0.02

Note: Intervention effect decreased with age: HR = 1.50 at age 20 and 1.23 at age 40.

Table 3. Push notifications effect varied by age group, with largest effect observed among 18 to 34 year-olds

Age Group	HR	95% CI	P-value
18-34	1.33	0.92 - 1.92	0.13
35-64	1.25	0.99 - 1.58	0.06
65+	0.82	0.65 - 1.03	0.08
All ages (crude)	1.12	0.96 - 1.29	0.15

Note: Wide CIs and non-significant p-values may reflect small sample sizes within subgroups.

Discussion

Key Findings and Future Directions

- **Findings:** Results varied by age, with stronger associations observed among **younger adults**.
- **Next Steps:** Future research will address challenges with participant selection *and* test other R/R modalities.

Limitations

- **Sample size:** Due to small sample size and issues with participant selection, interpret findings with caution.
- **Generalizability:** The sample was skewed towards regular vaccinators, limiting broader applicability.

Conclusion

- **Research Needed:** Pilot design was feasibility-focused, not conclusive. Larger studies are needed to assess effectiveness and explore how age and other factors (e.g., geography) modify intervention effectiveness.



docket[®]

AIRA Discovery Session
February 23, 2026

Contact Information

Francis Pacillo

fp2484@cumc.columbia.edu

Nathan Scott

nathan.scott@dockethealth.com

Monette Schwoerer

monette.schwoerer@alaska.gov




Impact of a Centralized Text Message Recall to Increase HPV Vaccine Series Completion Rates

Marisa Langdon-Embry, MSc
CIR Data Governance and Quality Assurance Analyst
Bureau of Immunization
New York City Department of Health and Mental Hygiene


American Immunization Registry Association Discovery Session
February 23, 2026

37,300 Cancers Are Caused by HPV Each Year

That equates to one person every 15 minutes, every day, all year long.



*Cancer in the back of the throat, including the base of the tongue and tonsils



Human papillomavirus (HPV) is very common.


- 13 million Americans are diagnosed with HPV each year. **More than half are between the ages of 15 and 24.**

HPV Vaccine

- Gardasil[®] (Merck); licensed in 2006
- Prevents more than 90% of HPV-related cancers
- Routinely recommended for 11-12-year-olds, prior to exposure to HPV
 - In July 2025, NYS and NYC started recommending HPV vaccination at age 9
 - 2-3 doses required
- HPV vaccination is not required for school in New York State

In New York City (NYC), on-time HPV vaccination rates are low

HPV Vaccination Coverage Rates Among NYC 13-Year-Olds by the 13th Birthday



Source: NYC Citywide Immunization Registry (numerators); 2022 Vintage Population Estimates (denominators)

Citywide Immunization Registry (CIR)

- NYC's Immunization Information System (IIS)
 - Implemented citywide in 1997
- Population-based
 - Birth certificates loaded into CIR twice per week
- Mandatory reporting of immunizations for children 0-18 years
- Contains
 - >15 million patient records
 - >180 million immunizations

Text messaging functionality was deployed in CIR in 2015.

A All patients in MyList

Specific Age

7-11 month olds 11-18 year olds
 19-35 month olds 13-17 year olds
 24-35 month olds 19+ year olds

Age Range

From ≥ years months
To < years months

DOB Range

Include patients born between
 / /
and
 / /

B **Gender**

Male
 Female

D **Enter the date range this message will run.**
NOTE: All recurrent jobs will run every 28 days from your start date. Once this job is created, you may stop future recurrent messages by turning off the job on the Reminder/Recall Job List.

From / /
To / /

C **For immunization series: Include patients who are missing:**

Any age-appropriate immunization

Any age-appropriate immunization from the series below only:

<input type="checkbox"/> Influenza	<input type="checkbox"/> Pneumo. Conjugate	<input type="checkbox"/> MMR
<input type="checkbox"/> HepB	<input type="checkbox"/> Pneumo. Polysaccharide	<input type="checkbox"/> Varicella
<input type="checkbox"/> Rotavirus	<input type="checkbox"/> Polio	<input type="checkbox"/> HepA
<input type="checkbox"/> DTaP	<input type="checkbox"/> Tdap	<input type="checkbox"/> Meningococcal
<input type="checkbox"/> Hib		<input type="checkbox"/> Human Papillomavirus

Include patients who do not have the # of specified valid doses from the series chosen below:

--0-- <input type="text"/> Influenza	--0-- <input type="text"/> Pneumo. Conjugate	--0-- <input type="text"/> MMR
--0-- <input type="text"/> HepB	--0-- <input type="text"/> Pneumo. Polysaccharide	--0-- <input type="text"/> Varicella
--0-- <input type="text"/> Rotavirus	--0-- <input type="text"/> Polio	--0-- <input type="text"/> HepA
--0-- <input type="text"/> DTaP	--0-- <input type="text"/> Tdap	--0-- <input type="text"/> Meningococcal
--0-- <input type="text"/> Hib		--0-- <input type="text"/> Human Papillomavirus

Select Message. This message will be sent to each patient on your recall list.

Use default message
Fill in the fields for the sample message provided.

Use custom message
Type in your message.

Your child born in CIR will insert patient birth YEAR here is overdue for immunization. To schedule, please call

FACILITY NAME (up to 33 characters):

Characters remaining: 33

at **CONTACT NUMBER:** .

132 character limit



Characters remaining: 132

NOTE: To allow patients to opt out of receiving text message reminders, the line "To stop reminders, text stop" will be added to the end of your message.

Patients who text "stop" will not receive any future text messages via the CIR.

Please note that it is your responsibility to adhere to the laws, rules, and regulations that apply to the disclosure of confidential and sensitive information in the content of your custom text message.

Cancel Clear Continue



Effectiveness of Text Message Reminder/Recall in the Literature

- Previous studies have found text messaging by healthcare providers or schools to be a successful method of recalling patients for HPV vaccination¹⁻⁶
- Few studies on text message recall by health departments

Study Aim & Objectives

- Aim: To evaluate the impact of centralized recall text message on HPV vaccine series completion rates among NYC adolescents who initiated the HPV series and were overdue for the second dose
- Objectives:
 1. To compare HPV vaccine series completion rates between adolescents whose parents/guardians were sent an HPV recall text message or a general health text message within 8 weeks
 2. To evaluate intervention effects among demographic subgroups

Methods

Study Design

- **Study Design:** Randomized Controlled Trial

Study Design

- **Study Design:** Randomized Controlled Trial
- **Data Source:** NYC Citywide Immunization Registry

Study Design

- **Study Design:** Randomized Controlled Trial
- **Data Source:** NYC Citywide Immunization Registry
- **Study Population:** NYC adolescents ages 11-14 years who received HPV dose 1 and were overdue for HPV dose 2
 - ***Intervention Group:*** Sent HPV vaccination recall text message
 - ***Control Group:*** Sent general health text message


Study Design

- **Study Design:** Randomized Controlled Trial
- **Data Source:** NYC Citywide Immunization Registry
- **Study Population:** NYC adolescents ages 11-14 years who received HPV dose 1 and were overdue for HPV dose 2
 - **Intervention Group:** Sent HPV vaccination recall text message
 - **Control Group:** Sent general health text message
- **Primary Outcome:** Proportion of adolescents completing the HPV vaccine series (dose 2 uptake) within 8 weeks of the text messages

Enrollment

Allocation

Analysis



Enrollment

Identified in CIR and
Assessed for Eligibility

Enrollment

Identified in CIR and
Assessed for Eligibility


Query Restrictions:

- Between ages 11-14 years
- Current NYC resident
- Valid mobile phone number in CIR record
- Did not opt out of text messaging

Enrollment


Identified in CIR and
Assessed for Eligibility

Enrollment



Enrollment


Allocation



Enrollment

Allocation

Analysis



Text Message Intervention

- On May 14, 2024, the NYC Health Department sent a one-time text message to parents of adolescents in both groups

Intervention Group

NYC Health, 311: Your child born in 2012 is due for their next HPV vaccine. Call your doctor today. To stop reminders, text STOP.

Control Group

NYC Health, 311: Beat the heat. Visit on.nyc.gov/nycheat or call [311](tel:311) for tips to stay healthy, safe and keep cool this summer. To stop reminders, text STOP.


Statistical Analysis Plan

- Primary analysis:
 - Compared HPV vaccine series completion rates at 8 weeks using a multivariable logistic regression model to adjust for confounders
 - A-priori covariates included age, sex, race/ethnicity, borough of residence and Vaccines For Children (VFC) eligibility status
- Secondary analysis:
 - Fit interaction models to evaluate the impact of the intervention on HPV vaccine series completion rates among demographic subgroups

Results

Enrollment

**Identified in CIR and
Assessed for Eligibility**
(n=355,412)



Enrollment


**Identified in CIR and
Assessed for Eligibility**
(n=355,412)

Excluded (n=333,182)

- Already completed series (n=149,028, 45%)
- Did not receive HPV dose 1 (n=133,855, 40%)
- Up-to-date (n=49,033, 15%)
- On 3-dose schedule (n=571, 0.2%)
- Duplicate phone number (n=695, 0.2%)

Enrollment


Allocation



Enrollment

Allocation

Analysis



Text message opt-out and failure rates were similar in both study arms

Text Job Summary	Intervention Group		Control Group	
	N	Percent (%)	N	Percent (%)
No. of Text Messages Sent	11,116	100%	11,114	100%
No. Successfully Delivered	9,378	84%	9,428	85%
No. Failed	1,507	16%	1,437	15%
Opt-outs	95	1%	66	0.70%

Demographic characteristics were similar in both arms at baseline, indicating successful randomization

Table 1: Baseline characteristics of study participants (n=22,230)

	Intervention Group n (%)	Control Group n (%)
Total	11,116 (100%)	11,114 (100%)
Age		
11-12 Years	3,893 (35.0%)	3,729 (33.6%)
13-14 Years	7,223 (65.0%)	7,385 (66.5%)
Sex		
Male	5,657 (50.9%)	5,769 (51.9%)
Female	5,448 (49.0%)	5,336 (48.1%)
Other	11 (0.1%)	9 (0%)
Race/Ethnicity		
Asian/Pacific Islander	1,105 (9.9%)	1,048 (9.4%)
Black, Non-Hispanic	2,779 (25.0%)	2,722 (24.5%)
Hispanic	4,505 (40.5%)	4,563 (41.1%)
Other	1,793 (16.1%)	1,812 (16.3%)
White, Non-Hispanic	934 (8.4%)	969 (8.7%)
Borough of Residence		
Manhattan	1,363 (12.3%)	1,433 (12.9%)
Bronx	3,162 (28.5%)	3,238 (29.1%)
Brooklyn	3,228 (29.0%)	3,166 (28.5%)
Queens	2,879 (25.9%)	2,832 (25.5%)
Staten Island	475 (4.3%)	442 (4.0%)
Missing	9 (0.1%)	3 (0%)
VFC Eligibility Status		
Yes	6,853 (61.7%)	6,994 (62.9%)
No	1,644 (14.8%)	1,564 (14.1%)
Unknown	2,619 (23.6%)	2,556 (23.0%)


Adolescents whose parents were sent the HPV recall text had 20% higher odds of completing the HPV vaccine series within 8 weeks compared to adolescents whose parents were sent the general health text

Study Arm	Total Participants	Vaccinated n (%)	Not Vaccinated n (%)	Unadjusted OR (95% CI)	Adjusted OR* (95% CI)
HPV recall text (Intervention group)	11,116	943 (8.5%)	10,173 (91.5%)	1.20 (1.08-1.32)	1.19 (1.07-1.31)
General health text (Control group)	11,114	800 (7.2%)	10,314 (92.8%)	-----	-----

*Adjusted for age, sex, race/ethnicity, borough of residence and VFC eligibility status


Who benefited the most from the HPV recall text message?

- Greatest impact among Asian/Pacific Islander, Hispanic, female, non-VFC eligible and residents in Staten Island and Brooklyn
- Less impact observed among Black, non-Hispanic, males, VFC eligible and residents in Manhattan, Bronx and Queens




A greater percentage of Asian/Pacific Islander, Hispanic, and White, non-Hispanic adolescents in the intervention group received HPV dose 2 compared to adolescents in the control group

Percent Vaccinated at 8 Weeks By Race/Ethnicity



A greater percentage of non-VFC eligible adolescents in the intervention group were vaccinated compared to adolescents in the control group



Key Findings

- The HPV vaccination recall text message increased HPV vaccine series completion rates among adolescents who were overdue for HPV vaccine
- There were notable disparities in series completion based on race/ethnicity, sex, borough of residence, and VFC eligibility status
 - Certain demographic groups may be more likely to benefit from a centralized text intervention
 - Additional outreach methods (i.e., phone calls, provider engagement) may be needed for less responsive groups

Limitations

- Text message available only in English language
- One-time text message
- Follow-up period coincided with summer break
- Looked only at HPV dose 2 uptake – results may not be generalizable to HPV series initiation or other vaccines

Strengths

- Large registry-based population
- Multivariable model
- Opt-out rates were low, indicating that intervention was well-tolerated
- Easy, low-cost intervention

Conclusions

- A centralized text message recall by a health department is a simple, low cost and well-tolerated strategy to increase vaccination rates
- Recommend using as a supplement to increase vaccine uptake among populations with low vaccination coverage

Thank you!

- Acknowledgements:

- Nilram Halat, Alexandra Ternier, Iris Cheng, Conner Jackson, Denise Benkel, Noora Majid, Kristin Oliver, Melissa Mickle-Hope, Alexa Riggs, Beth Rubenstein, Allison Lemkin, Michelle Macaraig, Bindy Crouch

- Contact info:

- mlangdonembry@health.nyc.gov

References

1. Glenn BA, Crespi CM, Herrmann AK, Nonzee NJ, Rosen DL, Park CL, Johnson G, Chang LC, Singhal R, Taylor VM, Bastani R. Effectiveness and feasibility of three types of parent reminders to increase adolescent human papillomavirus (HPV) vaccination. *Preventive Medicine*. 2023 Apr 1;169:107448.
2. Morris J, Wang W, Wang L, Peddecord KM, Sawyer MH. Comparison of reminder methods in selected adolescents with records in an immunization registry. *Journal of Adolescent Health*. 2015 May 1;56(5):S27-32.
3. Tull F, Borg K, Knott C, Beasley M, Halliday J, Faulkner N, Sutton K, Bragge P. Short message service reminders to parents for increasing adolescent human papillomavirus vaccination rates in a secondary school vaccine program: a randomized control trial. *Journal of Adolescent Health*. 2019 Jul 1;65(1):116-23.
4. Rand CM, Vincelli P, Goldstein NP, Blumkin A, Szilagyi PG. Effects of phone and text message reminders on completion of the human papillomavirus vaccine series. *Journal of Adolescent Health*. 2017 Jan 1;60(1):113-9.
5. Rand CM, Brill H, Albertin C, Humiston SG, Schaffer S, Shone LP, Blumkin AK, Szilagyi PG. Effectiveness of centralized text message reminders on human papillomavirus immunization coverage for publicly insured adolescents. *Journal of Adolescent Health*. 2015 May 1;56(5):S17-20.
6. Kharbanda EO, Stockwell MS, Fox HW, Andres R, Lara M, Rickert VI. Text message reminders to promote human papillomavirus vaccination. *Vaccine*. 2011 Mar 21;29(14):2537-41.

DAR 2026 Materials Are Now Available!

DAR 2026 Materials Are Now Available for IIS!

• Is your IIS looking for a **no-cost** way to dive into the quality of **patient-level and vaccine-level data**? Join the 27 jurisdictions that participated last year in **Data at Rest (DAR)** as part of AIRA's Measurement & Improvement initiative!

• DAR helps IIS:

- ✓ Assess data completeness, consistency, and timeliness
- ✓ Identify strengths and gaps in data quality
- ✓ Support data governance and improvement efforts

•  Take advantage of this opportunity to **benchmark your data and drive meaningful improvements**. New materials are available—don't miss out!

•  Learn more and get started today: [DAR 2026](https://repository.immregistries.org/resource/dar/)



Thank you to our presenters,
and thanks to all of you for
joining us!

Please complete a brief evaluation survey.

The next Discovery Session
will be on **March 23, 2026**